Correcting Metabolic & Inflammatory Imbalances for Healthy Lifespan
- Harnessing the SCAP/Insig1 pathway to downregulate SREBP-mediated lipogenesis, providing a direct physiological brake on fat accumulation that remains effective even after the intensive weight-loss phase of GLP-1 therapy is complete
- Utilizing miR-146a upregulation to mitigate hypothalamic senescence and systemic inflammation, restoring metabolic “resilience” and protecting against the weight-gain “rebound” triggered by standard hormonal therapies
- Implementing a low-dose, small molecule regimen that achieves a 55% reduction in visceral fat accumulation, offering an orally-deliverable maintenance solution that secures long-term cardiometabolic health and provides a clear value proposition for global payers